UroGen Pharma Ltd. Ordinary Shares (URGN)
FairStock Score: 31/100 — RISKY
Key Financials
| Current Price | $34.49 |
| Market Cap | $1.7B |
| P/E Ratio | -17.51 |
| ROE | —% |
| Dividend Yield | 0% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
As a value investor in the Buffett-Graham tradition, I start with durable earnings power and a margin of safety. UroGen is a 300-employee biotechnology company selling urothelial cancer therapies, including RTGel, mitomycin, and Zusduri. The top line is moving: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $72.5M versus $24.2M in fiscal Q2 2025, the quarter ended 2025-06-30; fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $51.0M. Full-year revenue rose from $82.7M in fiscal year 2023, the year ended 2023-12-31, to $90.4M in fiscal year 2024, the year ended 2024-12-31, and $109.8M in fiscal year 2025, the year ended 2025-12-31. Net losses are narrowing in recent quarters: -$14.4M in fiscal Q2 2026, the quarter ended 2026-06-30, versus -$49.9M in fiscal Q2 2025, the quarter ended 2025-06-30. That is real commercial progress.
In plain English: UroGen Pharma develops and sells treatments for bladder and related cancers. Revenue is growing and losses are shrinking, but the company still loses money and burns cash, so the business looks financially weak. At $38.26, the price is expensive compared with its current lack of profits.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash
Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer